ClinicalTrials.gov
public full text
Public Domain
A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy expansion, and open-label phase I clinical study assessing the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection （a humanized anti-PD-1 monoclonal antibody）in patients with advanced solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors#892838
- A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors#1322551
- A Study of QL1706 in Subjects With Advanced Malignant Tumor#1232057
- A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors#1046274
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma#1308340
Record · ID 1245021
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive